GlobalData on MSN7h
MSD reports topline outcomes from Phase III NSCLC trial of pembrolizumab
MSD has reported positive topline outcomes from the Phase III MK-3475A-D77 study assessing the noninferiority of subcutaneous ...
Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation
Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...
pharmaphorum8h
MSD says subcutaneous Keytruda matches IV form
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
The Pharma Letter22h
Subcutaneous Keytruda meets goals, says Merck
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
Cure Today13d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
Business Wire2d
Toragen, Inc. Provides Update on Data from Ongoing Phase 1 Clinical Trial of TGN-S11 as Monotherapy and in Combination with Keytruda® (pembrolizumab) in Patients with Stage 4 ...
The study is being conducted in two parts: Part 1 is escalating doses of TGN-S11 monotherapy and Part 2 is TGN-S11 in combination with Keytruda®, a PD-1 checkpoint inhibitor. The dose escalation ...
Merck announces ‘positive’ results from Phase 3 MK-3475A-D77 trial
Merck (MRK) announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of ...
Medpage Today on MSN7d
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...